The upgrade follows recent developments at Sentynl Therapeutics, a subsidiary of Zydus Lifesciences, which secured U.S. FDA ...

Ardelyx (ARDX) rose 12% on a report that Zydus Lifesciences is in talks to purchase the company. Zydus may seek to acquire control of Ardelyx or purchase selected molecules, according to a report from ...

Zydus Lifesciences on Wednesday has received approval from the US health regulator to market a generic diabetes drug in the ...

Zydus Lifesciences has received USFDA approval to market a generic diabetes drug, Dapagliflozin Tablets, in the US. The drug is indicated for improving glycemic control in adults with type 2 diabetes.

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Dapagliflozin Tablets, 5 mg and 10 mg (USRLD: Farxiga Tablets, 5 mg and 10 mg).

Net Sales at Rs 152.60 crore in December 2025 up 72.62% from Rs. 88.40 crore in December 2024. Quarterly Net Profit at Rs. 12.10 crore in December 2025 up 3.42% from Rs. 11.70 crore in December 2024.

Zydus has also made its first overseas consumer wellness acquisition, UK-based Comfort Click, for £239 million.

Anand Rathi trims its earnings estimate to factor in weaker margin and higher amortisation expenses for Comfort Click ...

ETHealthworld.com brings latest zydus cadila news, views and updates from all top sources for the Indian Health industry.

Discusses Zydus Collaboration, Global Manufacturing Expansion, and Patient Access Initiatives January 28, 2026 4:00 PM ...

Despite a net loss for the quarter, Other parameters of Zydus Wellness in Q3 were better from last year. Revenue increased to ₹965 crore from ₹462 crore during the same quarter last year, while its ...

Zydus Wellness Ltd has achieved a remarkable 113.7% year-on-year increase in consolidated net sales for Q3 FY26, bolstered by acquisitions. The company's EBITDA has skyrocketed by over 3x, marking ...